ALFQ
Sponsors
U.S. Army Medical Research and Development Command, National Institute of Allergy and Infectious Diseases (NIAID), Henry M. Jackson Foundation for the Advancement of Military Medicine
Conditions
ARTAcute HIV InfectionCampylobacter InfectionHIVHIV InfectionsHIV-1-infectionInfluenza PreventionPLWH
Phase 1
A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy Adults
NCT04268420
Start: 2020-03-20End: 2023-12-31Target: 46Updated: 2023-01-10
A Trial For The Study of Falciparum Malaria Protein 014 Administered Via Intramuscular Injection in Healthy Adults
NCT04296279
Start: 2020-03-20End: 2022-12-31Target: 46Updated: 2021-04-19
HIV Vaccine in HIV-uninfected Adults
CompletedNCT04658667
Start: 2022-02-03End: 2024-07-01Updated: 2025-07-30
Safety and Immunogenicity of CJCV2 With and Without ALFQ
CompletedNCT05500417
Start: 2022-09-13End: 2025-01-02Updated: 2026-04-01
Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission
WithdrawnNCT05769569
Start: 2023-09-01End: 2025-07-01Updated: 2024-05-03
RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV
RecruitingNCT06484335
Start: 2025-03-27End: 2027-08-01Target: 48Updated: 2025-09-16
Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
RecruitingNCT06863142
Start: 2025-04-28End: 2026-07-31Target: 45Updated: 2026-02-23